Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmceuticals Inc.filedCriticalAventis Pharmceuticals Inc.
Publication of YU15301ApublicationCriticalpatent/YU15301A/sh
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Postupak za lečenje jednog pacijenta od poremećaja spavanja davanjem pacijentu jedne delotvorne količineR-(+)- alfa-(2,3-dimeto ksifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanola ili neke njegove farmaceutski prihvatljive soli pacijentu kome je potrebno takvo lečenje.[The use of r (+) -α - (2,3- dimetoxyphfenil) -1-[2-(4- fluorophfenyl) ethyl]-4- piperidinementhanol for the treatment of sllep disordersthe process for treating a patient who suffers of sleep disorder is giving the patient effective dosage of R-(+)α-(2,3-dimetoxyphfenil)-1-[2-(4- fluorophenyl)ethyl]-4-piperidinementhanol or other pharmaceutically acceptable salts to the patient who is in need of such treatment.[The use of r (+) -α - (2,3- dimetoxyphfenil) -1-[2-(4- fluorophfenyl) ethyl]-4- piperidinementhanol for the treatment of sllep disordersthe process for treating a patient who suffers of sleep disorder is giving the patient effective dosage of R-(+)α-(2,3-dimetoxyphfenil)-1-[2-(4- fluorophenyl)ethyl]-4-piperidinementhanol or other pharmaceutically acceptable salts to the patient who is in need of such treatment.
YU15301A1988-09-281999-07-29PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
YU15301A
(sh)
Use of inhibitors of ornitine aminotransferase for the manufacture of a medicament for the treatment of alzheimer's disease and process to prepare (2s,5s)-5-fluoromethylornithine